NCT02084095

Brief Summary

Background Glucose metabolism abnormalities are frequent in acromegaly. Insulin resistance (IR) correlates with the intensity of acromegaly and Insulin-like Growth factor-I (IGF-I) correlates better with IR than growth hormone (GH). Insulin secretion (IS) is significantly reduced in hyperglycemic acromegalics as compared with those with normal glucose levels. IS is independent of acromegaly intensity. The aim of this study is to show that in active acromegaly: 1) IGF-I does not cause IR but is just a better marker of acromegaly intensity than GH; 2) high GH levels induce IR through free fatty acids (FFA); 3) hyperglycemia is caused by a defficient IS on a background of IR. Methods Intensity of acromegaly will be assessed using serum levels of GH, IGF-I and IGF binding globulin-3. IR and IS will be assessd using an intravenous glucose tolerance test acording to Bergman model. FFA will be directly measured in plasma.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
16

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Mar 2014

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2014

Completed
6 days until next milestone

First Submitted

Initial submission to the registry

March 7, 2014

Completed
4 days until next milestone

First Posted

Study publicly available on registry

March 11, 2014

Completed
5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2019

Completed
Last Updated

August 21, 2019

Status Verified

August 1, 2019

Enrollment Period

5 years

First QC Date

March 7, 2014

Last Update Submit

August 20, 2019

Conditions

Outcome Measures

Primary Outcomes (3)

  • The correlation coefficient between IGFBP-3 and insulin resistance assessed using Bergman model is non-inferior to the correlation coefficient between IGF-I and insulin resistance

    2 years

  • Free fatty acids correlates significantly with insulin resistance assessed using Bergman model

    2 years

  • Disposition index calculated using Bergman model is significantly reduced in subjects with glucose intolerance than in subjects with normal glucose tolerance

    2 years

Secondary Outcomes (5)

  • GH, IGF-I and IGFBP-3 significantly correlates with insulin resistance calculated using Bergman model

    2 years

  • GH, IGF-I and IGFBP-3 significantly correlates with free fatty acids

    2 years

  • GH, IGF-I and IGFBP-3 does not correlate with insulin sensitivity calculated using Bergman model

    2 years

  • GH, IGF-I and IGFBP-3 does not correlate with disposition index

    2 years

  • Disposition index after reduction of acromegaly activity by various treatments

    3 months after surgery or start of medical treatment

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

The study will prospectively include patients with active acromegaly assessed in a tertiary center. All patients who meet inclusion and exclusion criteria will be invited consecutively to participate in the study until the proposed number of patients is reached.

You may qualify if:

  • active acromegaly based on following criteria: minimum GH in oral glucose tolerance test (OGTT) over 1 ng/mL and serum IGF-I over upper limit of normal for age and sex
  • age between 18 and 65 years old

You may not qualify if:

  • more than one previous pituitary surgical intervention for acromegaly
  • present medical treatment for acromegaly (somatostatin analogs, GH-receptor blockers, dopaminergic agonists)
  • previous pituitary radiotherapy
  • present medical treatment for hyperglycemia (oral antidiabetic drugs, insulin, etc)
  • pituitary failure, treated or not
  • medical or surgical conditions which, in the oppinion of the principal investigator, could impact on study results or patient's safety
  • fasting blood glucose over 200 mg/dL or HbA1c over 8%.
  • body mass index less than 20 or over 35 kg/mp

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

"C. I. Parhon" Institute of Endocrinology

Bucharest, 011863, Romania

Location

MeSH Terms

Conditions

Acromegaly

Condition Hierarchy (Ancestors)

Bone Diseases, EndocrineBone DiseasesMusculoskeletal DiseasesHyperpituitarismPituitary DiseasesHypothalamic DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesEndocrine System Diseases

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Lecturer, PhD

Study Record Dates

First Submitted

March 7, 2014

First Posted

March 11, 2014

Study Start

March 1, 2014

Primary Completion

March 1, 2019

Study Completion

March 1, 2019

Last Updated

August 21, 2019

Record last verified: 2019-08

Locations